10 Best High Quality Low Pe Stocks for November 2025
Welcome to the Value Sense Blog, your resource for insights on the stock market! At Value Sense, we focus on intrinsic value tools and offer stock ideas with undervalued companies. Dive into our research products and learn more about our unique approach at valuesense.io
Explore diverse stock ideas covering technology, healthcare, and commodities sectors. Our insights are crafted to help investors spot opportunities in undervalued growth stocks, enhancing potential returns. Visit us to see evaluations and in-depth market research.
Market Overview & Selection Criteria
The 2025 market landscape is shaped by persistent macroeconomic uncertainty, sector rotation, and a renewed focus on quality fundamentals. Our selection methodology leverages ValueSense’s proprietary intrinsic value models, quality ratings, and advanced screeners to identify stocks with robust financial health, attractive valuations, and sectoral diversification. Each stock is evaluated on key metrics such as revenue growth, free cash flow, return on invested capital (ROIC), and debt profile, ensuring a balanced and data-driven watchlist[1][2].
Featured Stock Analysis
Novo Nordisk A/S (NVO)
| Metric | Value |
|---|---|
| Market Cap | $219.9B |
| Quality Rating | 6.5 |
| Intrinsic Value | $77.4 |
| 1Y Return | -55.8% |
| Revenue | DKK 311.9B |
| Free Cash Flow | DKK 62.0B |
| Revenue Growth | 20.9% |
| FCF margin | 19.9% |
| Gross margin | 83.9% |
| ROIC | 29.7% |
| Total Debt to Equity | 59.1% |
Investment Thesis
Novo Nordisk stands out as a global leader in diabetes care and chronic disease therapeutics, supported by a formidable market cap of $219.9B. The company’s robust revenue growth of 20.9% and high gross margin of 83.9% underscore its operational excellence. With a ValueSense quality rating of 6.5 and an intrinsic value of $77.4, NVO is positioned as an undervalued healthcare innovator with strong free cash flow (DKK 62.0B) and a healthy FCF margin of 19.9%. Its 1-year return is currently -55.8%, reflecting sector volatility but also potential for mean reversion as fundamentals remain solid.
Key Catalysts
- Continued global demand for diabetes and obesity treatments
- Expansion into new therapeutic areas
- Strong R&D pipeline and product launches
- High ROIC 29.7% supports reinvestment and growth
Risk Factors
- Currency fluctuations impacting international revenue
- Competitive pressures from biosimilars and generics
- Regulatory risks in key markets
- Moderate total debt to equity 59.1% requires monitoring
Merck & Co., Inc. (MRK)
| Metric | Value |
|---|---|
| Market Cap | $215.2B |
| Quality Rating | 7.1 |
| Intrinsic Value | $107.2 |
| 1Y Return | -15.3% |
| Revenue | $63.6B |
| Free Cash Flow | $14.7B |
| Revenue Growth | 1.8% |
| FCF margin | 23.1% |
| Gross margin | 81.2% |
| ROIC | 25.7% |
| Total Debt to Equity | 72.2% |
Investment Thesis
Merck & Co. is a pharmaceutical powerhouse with a $215.2B market cap and a ValueSense quality rating of 7.1. The company’s intrinsic value is estimated at $107.2, suggesting upside potential. Despite a modest 1-year return of -15.3%, Merck’s fundamentals remain resilient: $63.6B in revenue, $14.7B in free cash flow, and a robust FCF margin of 23.1%. Its gross margin of 81.2% and ROIC of 25.7% highlight operational efficiency, while a revenue growth rate of 1.8% reflects stability in a mature sector.
Key Catalysts
- Blockbuster drugs and expanding oncology portfolio
- Strategic acquisitions and pipeline development
- Strong cash flow generation for R&D and dividends
- High quality rating 7.1 signals consistent execution
Risk Factors
- Patent expirations and generic competition
- Regulatory headwinds in drug approvals
- Elevated total debt to equity 72.2%
- Slower revenue growth compared to peers
PDD Holdings Inc. (PDD)
| Metric | Value |
|---|---|
| Market Cap | $188.4B |
| Quality Rating | 6.8 |
| Intrinsic Value | $397.9 |
| 1Y Return | 11.8% |
| Revenue | CN¥409.6B |
| Free Cash Flow | CN¥94.2B |
| Revenue Growth | 19.9% |
| FCF margin | 23.0% |
| Gross margin | 57.4% |
| ROIC | (90.5%) |
| Total Debt to Equity | 3.0% |
Investment Thesis
PDD Holdings, with a market cap of $188.4B, is a leading Chinese e-commerce platform experiencing rapid expansion. The company boasts a ValueSense quality rating of 6.8 and an intrinsic value of $397.9. PDD’s 1-year return of 11.8% and revenue growth of 19.9% reflect strong momentum. Its free cash flow of CN¥94.2B and FCF margin of 23.0% support ongoing investments in technology and market share. Despite a negative ROIC -90.5%, the company’s low total debt to equity 3.0% signals prudent financial management.
Key Catalysts
- Accelerated adoption of e-commerce in China
- Expansion into international markets
- Technology-driven operational efficiencies
- Strong cash flow generation
Risk Factors
- Intense competition in Chinese and global e-commerce
- Regulatory scrutiny in China’s tech sector
- Negative ROIC indicates capital allocation challenges
- Currency and geopolitical risks
Unilever PLC (UL)
| Metric | Value |
|---|---|
| Market Cap | $148.9B |
| Quality Rating | 7.3 |
| Intrinsic Value | $95.9 |
| 1Y Return | 0.4% |
| Revenue | €120.1B |
| Free Cash Flow | €14.5B |
| Revenue Growth | 2.5% |
| FCF margin | 12.1% |
| Gross margin | 71.3% |
| ROIC | 32.1% |
| Total Debt to Equity | 160.7% |
Investment Thesis
Unilever, a global consumer goods giant, commands a $148.9B market cap and a ValueSense quality rating of 7.3. With an intrinsic value of $95.9 and a stable 1-year return of 0.4%, UL offers defensive characteristics. The company’s €120.1B in revenue, €14.5B in free cash flow, and a gross margin of 71.3% highlight its scale and efficiency. Revenue growth of 2.5% and a high ROIC of 32.1% reinforce its status as a steady compounder in the consumer staples sector.
Key Catalysts
- Global brand portfolio and pricing power
- Expansion in emerging markets
- Operational efficiencies and cost management
- High quality rating and ROIC
Risk Factors
- Currency volatility impacting international sales
- High total debt to equity 160.7%
- Slower growth in mature markets
- Exposure to commodity price fluctuations
Anheuser-Busch InBev SA/NV (BUD)
| Metric | Value |
|---|---|
| Market Cap | $121.4B |
| Quality Rating | 7.1 |
| Intrinsic Value | $71.9 |
| 1Y Return | 2.6% |
| Revenue | $73.5B |
| Free Cash Flow | $11.7B |
| Revenue Growth | 22.7% |
| FCF margin | 15.9% |
| Gross margin | 55.7% |
| ROIC | 17.3% |
| Total Debt to Equity | 82.7% |
Investment Thesis
Anheuser-Busch InBev, with a $121.4B market cap and a ValueSense quality rating of 7.1, is a dominant force in the global beverage industry. The company’s intrinsic value is $71.9, and its 1-year return is 2.6%. BUD’s $73.5B in revenue, $11.7B in free cash flow, and a revenue growth rate of 22.7% reflect a strong rebound post-pandemic. Its FCF margin of 15.9% and gross margin of 55.7% support ongoing brand investments.
Key Catalysts
- Global distribution and leading beer brands
- Recovery in on-premise consumption
- Operational cost savings and synergies
- Revenue growth outpacing sector averages
Risk Factors
- High total debt to equity 82.7%
- Exposure to commodity price volatility
- Regulatory and ESG pressures
- Currency risks in emerging markets
British American Tobacco p.l.c. (BTI)
| Metric | Value |
|---|---|
| Market Cap | $113.4B |
| Quality Rating | 7.4 |
| Intrinsic Value | $139.0 |
| 1Y Return | 49.3% |
| Revenue | £37.9B |
| Free Cash Flow | £11.7B |
| Revenue Growth | (30.9%) |
| FCF margin | 30.9% |
| Gross margin | 83.1% |
| ROIC | 14.3% |
| Total Debt to Equity | 74.9% |
Investment Thesis
British American Tobacco, with a $113.4B market cap and the highest ValueSense quality rating in this list 7.4, is a leading player in the global tobacco industry. The company’s intrinsic value is $139.0, and its 1-year return is an impressive 49.3%. Despite a revenue decline of 30.9%, BTI maintains a high FCF margin of 30.9% and a gross margin of 83.1%. Its ROIC of 14.3% and stable free cash flow £11.7B support ongoing shareholder returns.
Key Catalysts
- Strong cash flow for dividends and buybacks
- Expansion into reduced-risk products
- High gross and FCF margins
- Attractive valuation relative to peers
Risk Factors
- Regulatory headwinds and declining smoking rates
- Currency and geopolitical risks
- High total debt to equity 74.9%
- ESG concerns impacting investor sentiment
Altria Group, Inc. (MO)
| Metric | Value |
|---|---|
| Market Cap | $94.9B |
| Quality Rating | 7.1 |
| Intrinsic Value | $96.1 |
| 1Y Return | 5.5% |
| Revenue | $20.2B |
| Free Cash Flow | $11.6B |
| Revenue Growth | (1.0%) |
| FCF margin | 57.4% |
| Gross margin | 72.0% |
| ROIC | 90.7% |
| Total Debt to Equity | (68.3%) |
Investment Thesis
Altria Group, with a $94.9B market cap and a ValueSense quality rating of 7.1, is a major U.S. tobacco company. The company’s intrinsic value is $96.1, and its 1-year return is 5.5%. MO’s $20.2B in revenue, $11.6B in free cash flow, and a remarkable FCF margin of 57.4% highlight its cash-generative business model. Its gross margin of 72.0% and ROIC of 90.7% are among the highest in the sector.
Key Catalysts
- Strong dividend yield and shareholder returns
- Expansion into non-combustible products
- High FCF and ROIC metrics
- Defensive sector positioning
Risk Factors
- Declining cigarette volumes
- Regulatory and litigation risks
- Negative total debt to equity -68.3%
- ESG and social responsibility concerns
Newmont Corporation (NEM)
| Metric | Value |
|---|---|
| Market Cap | $88.8B |
| Quality Rating | 7.7 |
| Intrinsic Value | $77.1 |
| 1Y Return | 80.3% |
| Revenue | $21.3B |
| Free Cash Flow | $6,122.0M |
| Revenue Growth | 26.0% |
| FCF margin | 28.8% |
| Gross margin | 45.6% |
| ROIC | 14.9% |
| Total Debt to Equity | 16.9% |
Investment Thesis
Newmont Corporation, the world’s largest gold miner, has a market cap of $88.8B and a ValueSense quality rating of 7.7. With an intrinsic value of $77.1 and a stellar 1-year return of 80.3%, NEM is a prime beneficiary of rising gold prices and inflation hedging. The company’s $21.3B in revenue, $6.1B in free cash flow, and a revenue growth rate of 26.0% highlight its strong fundamentals. Its FCF margin of 28.8% and ROIC of 14.9% support ongoing capital returns.
Key Catalysts
- Rising gold prices amid macro uncertainty
- Operational scale and cost leadership
- Strong free cash flow for dividends and buybacks
- High quality rating 7.7 and sector leadership
Risk Factors
- Commodity price volatility
- Environmental and regulatory risks
- Capital-intensive operations
- Moderate total debt to equity 16.9%
Sarcos Technology and Robotics Corporation (STRC)
| Metric | Value |
|---|---|
| Market Cap | $73.3B |
| Quality Rating | 5.9 |
| Intrinsic Value | $26.2 |
| 1Y Return | 10.5% |
| Revenue | $355.0M |
| Free Cash Flow | ($50.8M) |
| Revenue Growth | 4,468.3% |
| FCF margin | (14.3%) |
| Gross margin | 69.5% |
| ROIC | 26.7% |
| Total Debt to Equity | 0.2% |
Investment Thesis
Sarcos Technology and Robotics, with a $73.3B market cap and a ValueSense quality rating of 5.9, is an emerging player in robotics and automation. The company’s intrinsic value is $26.2, and its 1-year return is 10.5%. STRC’s revenue growth of 4,468.3% signals explosive expansion, though from a low base. Its gross margin of 69.5% and ROIC of 26.7% are promising, but negative free cash flow -$50.8M and a low FCF margin -14.3% highlight early-stage risks.
Key Catalysts
- Rapid adoption of robotics in industrial applications
- Strategic partnerships and technology innovation
- High revenue growth and improving margins
- Minimal debt (total debt to equity 0.2%)
Risk Factors
- Negative free cash flow and early-stage losses
- Execution risk in scaling operations
- Competitive pressures in robotics sector
- Volatile revenue base
MicroStrategy Incorporated (MSTR)
| Metric | Value |
|---|---|
| Market Cap | $73.3B |
| Quality Rating | 6.4 |
| Intrinsic Value | $179.8 |
| 1Y Return | 10.2% |
| Revenue | $474.9M |
| Free Cash Flow | ($18.1B) |
| Revenue Growth | 1.6% |
| FCF margin | (3,819.0%) |
| Gross margin | 70.1% |
| ROIC | 24.7% |
| Total Debt to Equity | 0.2% |
Investment Thesis
MicroStrategy, with a $73.3B market cap and a ValueSense quality rating of 6.4, is a software company known for its aggressive Bitcoin holdings. The company’s intrinsic value is $179.8, and its 1-year return is 10.2%. MSTR’s $474.9M in revenue and gross margin of 70.1% reflect a stable core business, but negative free cash flow -$18.1B and a very low FCF margin -3,819.0% highlight the impact of its capital allocation strategy. Its ROIC of 24.7% and minimal debt (total debt to equity 0.2%) are positives.
Key Catalysts
- Leverage to Bitcoin price movements
- Enterprise software growth opportunities
- High gross margin and ROIC
- Low financial leverage
Risk Factors
- Volatility from cryptocurrency exposure
- Negative free cash flow and capital allocation risks
- Regulatory scrutiny of digital assets
- Narrow business focus
Portfolio Diversification Insights
This watchlist spans healthcare, consumer staples, technology, commodities, and emerging robotics, providing sectoral balance and risk mitigation. Healthcare (NVO, MRK) and consumer staples (UL, BUD, BTI, MO) offer defensive characteristics, while technology (PDD, STRC, MSTR) and commodities (NEM) add growth and inflation protection. The mix of mature cash generators and high-growth disruptors supports a diversified approach to market cycles.
Market Timing & Entry Strategies
Market timing remains challenging, but ValueSense’s intrinsic value tools and backtesting features can help identify attractive entry points based on valuation gaps and historical performance[1][2]. Consider dollar-cost averaging for volatile names and monitor sector rotation trends. Entry strategies should be aligned with individual risk tolerance and investment horizons, leveraging ValueSense’s charting and screening tools for ongoing analysis.
Explore More Investment Opportunities
For investors seeking undervalued companies with high fundamental quality, our analytics team provides curated stock lists:
📌 50 Undervalued Stocks (Best overall value plays for 2025)
📌 50 Undervalued Dividend Stocks (For income-focused investors)
📌 50 Undervalued Growth Stocks (High-growth potential with strong fundamentals)
🔍 Check out these stocks on the Value Sense platform for free!
More Articles You Might Like
- How VKTX (Viking Therapeutics) Makes Money in 2025: A Deep-Dive With Income Statement
- How NET (Cloudflare) Makes Money in 2025: A Deep-Dive With Income Statement
- How MASS (908 Devices) Makes Money in 2025: A Deep-Dive With Income Statement
- How CRVO (CervoMed) Makes Money in 2025: A Deep-Dive With Income Statement
- How GILD (Gilead Sciences) Makes Money in 2025: A Deep-Dive With Income Statement
FAQ Section
Q1: How were these stocks selected?
Stocks were chosen using ValueSense’s proprietary screeners, focusing on intrinsic value, quality ratings, and fundamental metrics such as revenue growth, free cash flow, and ROIC[1][2].
Q2: What's the best stock from this list?
Each stock offers unique strengths; Newmont Corporation (NEM) currently stands out for its high quality rating 7.7 and strong 1-year return, but suitability depends on individual investment goals.
Q3: Should I buy all these stocks or diversify?
Diversification across sectors and risk profiles is recommended for educational portfolio construction, as it helps mitigate sector-specific risks and smooth returns.
Q4: What are the biggest risks with these picks?
Risks include sector-specific headwinds, regulatory changes, currency volatility, and company-specific execution challenges. Each stock’s risk profile is detailed in its analysis.
Q5: When is the best time to invest in these stocks?
Optimal timing depends on valuation, market conditions, and personal risk tolerance. ValueSense’s intrinsic value and charting tools can help identify attractive entry points based on data-driven analysis[1][2].